EGFR and colorectal cancer: With the aim of developing effective preclinical models for testing possible strategies to prevent and/or overcome acquired resistance to EGFR blockade, we have concentrated our efforts on three human colorectal cancer cell lines (SW48, LIM1215 and CACO2) that are sensitive to EGFR inhibition [15, 16, 21, 22].